Adaptive Risk Models
Adaptive Risk Models for Early Cancer Detection
Discover how adaptive risk models are transforming early cancer detection by continuously learning from evolving clinical data. Explore intelligent diagnostic approaches that improve risk assessment, support personalized screening strategies, and enable more informed clinical decisions.
Abstract
Most blood-based cancer detection tests are locked at launch, even though the populations,
assays and clinical practices around them keep changing. We argue that multi-analyte early-
detection models should be adaptive: recalibrated as outcome-linked results accumulate, and
governed by versioning, human-gated updates, drift monitoring and documented re-validation.
Introduction
A diagnostic classifier is a snapshot. It learns from a fixed set of samples gathered at particular
sites, with particular assays, from a particular mix of patients. It is then locked, validated and
used for years. This model fits less well with modern multi-analyte liquid biopsies, which combine circulating tumor DNA, protein biomarkers and clinical features in machine-learned models.
Why Pancreatic Cancer Is the Hard Case
Pancreatic ductal adenocarcinoma (PDAC) shows both the promise and the difficulty. Most
patients are diagnosed at an advanced stage, when curative surgery is no longer possible, and
outcomes remain poor. Detecting stage I disease could change the prognosis, but the disease
is uncommon in the general population.
The Case for Adaptive Models
By an adaptive risk model we mean a multi-analyte classifier whose calibration, and sometimes
its feature weighting, is periodically updated as new results with confirmed outcomes become
available. In practice this means biopsy-confirmed diagnoses, or adequate clinical follow-up
for people without cancer.
Governance and Safety
Adaptive models can and should operate within existing U.S. regulatory frameworks. In
CLIA-regulated laboratories, adaptive modifications can be managed through standard validation and change-control practices. The FDA’s Predetermined Change Control Plan (PCCP) provides a clear pathway for pre-specifying the types of model changes, the data that will trigger them, and the performance criteria that must be met.
Limitations and Conclusion
Adaptive models are not a replacement for clinical judgment. Evidence from real-world use will
still be essential to confirm long-term benefit, understand how updates affect performance across diverse populations, and ensure that changes improve patient outcomes.
Declarations
Conflict of Interest: The authors are employees and shareholders of Early Signal Diagnostics, Inc.
Funding: This work was funded by Early Signal Diagnostics, Inc. and New Century Diagnostics, Inc.
Ethics: This work involves no human subjects.
Data Availability: No new data were generated or analyzed.
Author Contributions: All authors contributed to the conception, writing, and review of the manuscript.
Use of Artificial Intelligence: Generative Al tools were not used in the creation of this manuscript.